Business ❯ Finance ❯ Investments

Biotechnology

Clinical Trials Pharmaceuticals Gene Editing CRISPR Therapeutics Psychedelics Stock Market Mergers and Acquisitions Biogen Inc Corporate Governance Asset Management

Serina Therapeutics Shares Jump After Private Placement to Raise Up to $63.3 Million

Proceeds target the registrational Phase 1b of SER-252 for advanced Parkinson’s under a 505(b)(2) pathway following first-patient dosing.

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

ARK Invest Deepens Pivot to AI With Fresh Buys in Tempus, WeRide and Kodiak, Cuts Twist and 10x

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing

Cathie Wood’s ARK Buys $24 Million of CoreWeave After Guidance Cut

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

ARK Invest Trims Tesla, AMD as It Adds Circle, BitMine and Bullish in Multi‑Day Shift

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Moonlake Shares Plunge on Mixed Phase 3 Results for Hidradenitis Drug

Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook

Bavarian Nordic Secures Major Contract for Smallpox and Mpox Vaccines